Subcutaneous MSC303 for immune-related kidney disease
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new medication called MSC303, given as a shot under the skin, for people with two kinds of immune-related kidney diseases. The goal is to see if it can help control the disease and improve kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with either lupus nephritis or ANCA-associated glomerulonephritis (a type of kidney inflammation).
- You have adequate organ function (your kidneys, liver, and other organs are working well enough).
- You have not had a severe allergic reaction to humanized monoclonal antibodies or any ingredient in the study drug.
- You do not have an active infection requiring antibiotics.
- You do not have a congenital immunoglobulin deficiency (a rare immune problem).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called HSK39297 combined with standard treatments (steroids and mycophenolate mofetil) for people with active lupus nephritis. It aims to see if the combination is safe and effective in reducing kidney inflammation.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This study tests an investigational drug called MTM-H-001 given as an injection to adults with certain autoimmune diseases caused by B cells (a type of immune cell). It aims to see if the drug is safe and works for conditions like lupus or rheumatoid arthritis, and could potentially help calm the immune system.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
This trial tests whether donated (allogeneic) stem cells can improve lupus nephritis, a kidney complication of lupus. It is for adults whose lupus kidney disease has not responded well to standard treatments or has come back, and it requires signs of active disease.
This trial tests a new medicine called SIM0278 for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the drug can help control the disease and improve kidney health.
Hear when a new Lupus Nephritis (LN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.